Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Core Viewpoint - Fortress Biotech and its subsidiary Cyprium Therapeutics have entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $205 million, which will be received upon closing of the transaction [1] Group 1: Transaction Details - Cyprium Therapeutics has sold its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million [1] - The PRV was issued following the FDA approval of ZYCUBO on January 12, 2026, and was transferred to Cyprium as part of the agreement with Sentynl Therapeutics [1] - The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act [1] Group 2: Financial Implications - Cyprium is eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl [1] - Cyprium is obligated to pay 20% of the proceeds from the PRV sale to the Eunice Kennedy Shriver National Institute of Child Health and Human Development [1]